Skip to main content
2076 Suchergebnisse für:

Ramucirumab 

sortieren nach |
"Aktualität" sortiert die Ergebnisse nach Publikationsdatum. "Relevanz" berücksichtigt auch noch andere Faktoren wie zum Beispiel die Häufigkeit der Suchbegriffe im Text.
  1. 04.04.2024 | Ramucirumab | ProductNotes

    Ramucirumab: wirksame bei Magenkarzinomen und NSCLC

  2. Open Access 15.04.2024 | Online First

    Real-World Effectiveness and Safety of Ramucirumab as a Second-Line Treatment for Patients with Unresectable Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma in Japan and South Korea: A Systematic Literature Review

    Gastric cancer is the fifth most common malignancy and the fourth leading cause of cancer death worldwide, with 1.09 million new cases and 0.77 million deaths in 2020 [ 1 ]. There is a heavy burden of gastric cancer in Eastern Asia, which has the …

  3. 01.01.2024 | News

    Ramucirumab

    Gastrocolic fistula
  4. 11.03.2024 | Online First

    Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients

    Lung cancer has a poor prognosis, and the number of patients with lung cancer is increasing worldwide [ 1 ]. In particular, the number of older patients with lung cancer is increasing owing to the aging of the population and the extension of …

  5. 04.09.2023 | OriginalPaper

    Efficacy and safety of trifluridine/tipiracil plus ramucirumab in comparison with trifluridine/tipiracil monotherapy for patients with advanced gastric cancer–single institutional experience

    Gastric cancer is the fourth leading cause of cancer death in the world and the fifth most common malignant tumor [ 1 ]. Combination regimens including a fluoropyrimidine and a platinum agent plus nivolumab for HER2-negative cases or trastuzumab …

  6. Open Access 01.12.2023 | OriginalPaper

    Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415)

    Gastro-esophageal adenocarcinoma (GEA) is the fifth most common cancer worldwide, causing over one million new cases (1,033,701) each year and is the third-leading cause of cancer death (about 782,685 deaths and 8.2% of total in 2018) [ 1 ].

  7. 01.06.2023 | News

    Ramucirumab

    Treatment failure: case report
  8. Open Access 01.12.2023 | OriginalPaper

    Prior treatment with oxaliplatin-containing regimens and higher total bilirubin levels are risk factors for neutropenia and febrile neutropenia in patients with gastric or esophagogastric junction cancer receiving weekly paclitaxel and ramucirumab therapy: a single center retrospective study

    Gastric cancer (GC) is one of the most common cancers with the fifth highest incidence and fourth highest mortality worldwide [ 1 ]. In Japan, it accounts for the second highest morbidity and third highest mortality [ 2 ]. Taxanes (paclitaxel (PTX) …

  9. 17.07.2023 | OriginalPaper

    Effect of massive ascites on ramucirumab pharmacokinetics in patients with gastrointestinal cancers: a population pharmacokinetic analysis

    Ramucirumab, a fully human immunoglobulin G (IgG) 1 monoclonal antibody that targets vascular endothelial growth factor receptor 2, is used to treat a range of cancers, including gastrointestinal cancers [ 1 – 4 ]. As a valuable antiangiogenic …

  10. 01.05.2023 | News

    Ramucirumab

    Ischaemic stroke: case report
  11. Open Access 01.12.2023 | OriginalPaper

    Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G)

    Gastric cancer (GC) is the fifth most common and fourth most deadly cancer worldwide [ 1 ]. It is more common in East Asia than in the Western countries. It is difficult to cure in patients with recurrent or unresectable GC or esophagogastric …

  12. 16.02.2023 | Magenkarzinom | ProductNotes
    Fortgeschrittenes Magenkarzinom

    Ramucirumab auch nach Immuntherapie wirksam

  13. 01.05.2023 | News

    Ramucirumab

    Anaphylaxis: case report
  14. Open Access 27.04.2023 | OriginalPaper

    Post-Marketing Safety Study of Ramucirumab Plus FOLFIRI: Analysis of Age and Initial Dose of Irinotecan in Patients with Metastatic Colorectal Cancer

    The standard of care for metastatic colorectal cancer (mCRC) is chemotherapy, either in combination or as single agents. Irinotecan is one of the key agents to be approved for the systemic treatment of mCRC; however, it is frequently accompanied …

  15. 14.12.2022 | Magenkarzinom | ProductNotes
    Fortgeschrittenes Magenkarzinom

    Antiangiogene Therapie mit Ramucirumab

    Der Zweitlinienstandard Ramucirumab plus Paclitaxel wirkt unabhängig von einer Vorbehandlung mit einer immunonkologischen (IO) Therapie oder einer gegen HER2 gerichteten Therapie.

  16. Open Access 15.09.2022 | OriginalPaper

    Correlation Between Tumor Response and Survival Outcomes in Patients with Advanced Gastric Cancer Receiving Ramucirumab and Paclitaxel as Second-Line Therapy

    Gastric cancer (GC) is the fifth most common cancer and the third leading cause of cancer death worldwide [ 1 ]. The high mortality rate in GC is mainly due to the lack of specific early manifestations, subsequently leading to the late diagnosis …

  17. Open Access 01.12.2023 | OriginalPaper

    A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFR-mutated, non–small cell lung cancer

    According to GLOBOCAN 2020, lung cancer is the second most common cancer and the leading cause of cancer-related death worldwide [ 1 ]. Non–small cell lung cancer (NSCLC) accounts for nearly 85% of primary lung cancer cases. NSCLC ‘tends to …

  18. 01.06.2023 | OriginalPaper

    Impact of prior bevacizumab therapy on the incidence of ramucirumab-induced proteinuria in colorectal cancer: a multi-institutional cohort study

    Colorectal cancer (CRC) is the second leading cause of cancer-related deaths worldwide, and the 5-year relative survival rate of patients with metastatic disease is 15% [ 1 , 2 ]. In the past two decades, remarkable progress has been made in the …

  19. Open Access 01.12.2023 | OriginalPaper

    Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma

    Liver cancer has the sixth highest incidence among malignant tumors and the third highest in mortality rate worldwide with 781,631 deaths per year, and hepatocellular carcinoma (HCC) is the most common primary liver malignancy [ 1 ]. Monitoring …

  20. Open Access 17.06.2023 | OriginalPaper

    Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study

    In 2020, lung cancer was the second most common cancer worldwide, with approximately 2.21 million new cases, and was associated with the highest number of cancer deaths at 1.80 million [ 1 ]. In Taiwan, lung cancer has the highest mortality rate of …

Suchergebnisse filtern:

e.Medpedia

Magenkarzinom beim alten und geriatrischen Patienten

Geriatrische Onkologie
Das Magenkarzinom tritt in höherem Alter häufiger auf, so dass bei steigender Lebenserwartung die Behandlung des geriatrischen onkologischen Patienten zunehmend wichtig wird. Die aus Studien etablierten Konzepte repräsentieren häufig nicht die Besonderheiten im Alter. Anhand verschiedener Studien bei älteren Patienten sowie Subgruppenanalysen und gepoolten Analysen soll im folgenden Kapitel die Evidenz der Therapie beim Magenkarzinom für ältere Patienten genauer beleuchtet werden.

weitere e.Medpedia Einträge

Suchoperatoren:

„ ... ... “ Findet Dokumente mit genau dieser Wortgruppe in exakt dieser Schreibweise und Reihenfolge (z.B., "rheumatische Beschwerden").
AND / UND Findet Dokumente, in denen beide Begriffe zusammen vorkommen (z.B., alkohol UND demenz).
OR / ODER Findet Dokumente, in denen einer der beiden oder beide Begriffe vorkommen (z.B., hiv ODER aids).
Leerzeichen Findet Dokumente, in denen alle Begriffe vorkommen. Der Leerschritt wird als UND interpretiert (z.B., isolierte systolische hypertonie).
NOT / NICHT Findet Dokumente, in denen der Begriff nach NOT nicht vorkommt (z.B., sars NOT sars-cov-2).
COUNT(...)>n Findet Dokumente, in denen der gesuchte Begriff mehr als n mal vorkommt. n steht für eine beliebige Anzahl (z.B., COUNT(mammakarzinom)>8).
NEAR(..., ..., ) Findet Dokumente, in denen beide Begriffe in beliebiger Reihenfolge innerhalb von maximal n Worten zueinander stehen. Empfehlung: wählen Sie zwischen 15 und 30 als maximale Wortanzahl (z.B., NEAR(covid, diabetes,20)).
* Findet Dokumente, in denen der Begriff in Wortvarianten vorkommt, wobei diese VOR, HINTER oder VOR und HINTER dem Suchbegriff anschließen können (z.B., thrombose*, *thrombose, *thrombose*).
? Findet Dokumente mit dem Suchbegriff in verschiedenen Schreibweisen, hier mit s oder z, also organisation und organization. Das ? steht für eine einzige Stelle (z.B., organi?ation).
& + - Sonderzeichen werden als UND interpretiert (z.B., Diagnose + Therapie).

Sie können Operatoren mit Ihrer Suchanfrage kombinieren, um diese noch präziser einzugrenzen.

Fahren Sie mit der Maus über den Suchoperator, um eine Erklärung seiner Funktionsweise anzuzeigen.